|
|
||||||||
1 Institute for Medical
Psychology, The present study investigated the
mechanisms by which conditioned immunosuppression enhances the
effectiveness of cyclosporin A (CsA) treatment in prolonging heart
allograft survival. Dark Agouti rats that were administered
subtherapeutic CsA (7 × 2 mg/kg on alternate days) rejected heart
allografts at the same time as non-CsA-treated rats. The addition of a
behavioral conditioning regimen (conditioned stimulus, saccharin;
unconditioned stimulus, 20 mg/kg CsA) to the subtherapeutic CsA
protocol produced a significant prolongation of graft survival,
including long-term survival (>100 days) in 20% of the animals.
Prior sympathetic denervation of the spleen completely blocked this
effect. In nontransplanted rats both conditioning and CsA treatment
reduce interleukin-2 and interferon (IFN)-
classical conditioning; heart transplantation; cytokine; interferon- BEHAVIORAL OR CLASSICAL conditioning is an associative
learning paradigm. Conditioning involves the pairing of a benign novel stimulus (conditioned stimulus, CS) with a stimulus that produces physiological changes (unconditioned stimulus, UCS). On re-presentation of the CS, the organism produces physiological alterations that are
usually ascribed to the UCS. This paradigm has been implemented to
produce conditioned alterations in immune functions (2). Commonly,
animals are presented with a sweet taste (saccharin) in the drinking
water and subsequently injected with a pharmacological agent that
produces changes in immune status. At a later date, the saccharin
solution is re-presented, at which time the animals avoid the stimulus
(conditioned taste aversion) and experience concomitant alterations in
immune function concordant with the effect of actual drug administration.
Conditioned effects have been demonstrated both in humoral and cellular
immunity (2). Furthermore, a limited number of studies have attempted
to examine the clinical relevance of conditioned changes in immune
function. Specifically, the morbidity and mortality of animals with
autoimmune disease are abated via conditioning with cyclophosphamide as
the UCS (1). Furthermore, the survival of heterotopic heart allografts
can be extended using a conditioning paradigm that pairs saccharin as
the CS with cyclosporin A (CsA) as the UCS (8, 12). Despite such
biologically relevant findings, a common criticism of the results from
conditioning experiments is that the effects are relatively small in
comparison to actual drug administration, and thus it is doubtful that
conditioning has any clinical relevance as a stand-alone therapy.
Nevertheless, the ability of a suboptimal, albeit therapeutic, dose of
cyclophosphamide to inhibit the development of systemic lupus
erythematosus in mice is enhanced by behavioral conditioning (1).
Therefore, we extended these data by examining whether a combination of
conditioning and subtherapeutic CsA treatment can prolong heterotopic
heart allograft survival in rats.
Furthermore, the mechanisms of conditioned changes in immune function
and disease progression are poorly understood. There is some evidence
for the role of endocrine mediators such as opioids and catecholamines
(16, 19); however, the results are inconclusive. One alternative
hypothesis is that conditioning produces its effect via the autonomic
innervation of lymphoid organs, where neurotransmitters and
neuropeptides such as catecholamines (22) are released in close
proximity to immunocompetent cells (10, 25). Catecholamines alter
immune function via binding to functional adrenoceptors on lymphocytes
(3, 11, 14). We have previously demonstrated that surgical denervation
of sympathetic input to the spleen abrogated the conditioned inhibition
of splenocyte proliferation and cytokine [interleukin (IL)-2 and
interferon (IFN)- Animals. Experimentally naive male
Dark Agouti (DA) and Lewis rats (LEW; Harlan Laboratories, Borchen,
Germany) weighing between 220 and 250 g were used. All rats were
allowed to habituate for 3 wk before experimentation. Animals were
individually housed in standard plastic-based laboratory cages (40 × 26 × 15 cm high) with a wire mesh lid. Cages were kept in
an air-conditioned, soundproofed holding room at an ambient temperature
of 24.0 ± 0.5°C. The animals had access to standard lab chow
and tap water ad libitum except during the water deprivation phase of
the experiment. A 12:12-h light cycle was maintained throughout the
experiment, with lights off at 0700. This allowed stimuli presentation
to be conducted during the dark (active) cycle of the animals. All
conditioning procedures were completed under red light so as to avoid
any interruption to the normal light-dark cycle of the rats.
Conditioning paradigm: analysis of corticosterone,
CsA, and intracellular IFN-
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
in the supernatant of
proliferating splenocytes. Additionally, therapeutic CsA treatment
decreased the number of IFN-
-producing
CD4+ naive and memory T cells in
the spleen. In contrast, behavioral conditioning increased that number.
These data indicate that behavioral conditioning prolongs heart
allograft survival by inhibiting the release of these cytokines in the
spleen via sympathetic innervation, supplementing the inhibited
cytokine production induced by CsA treatment.
; graft survival
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
] production (8). Therefore, we examined
whether the conditioned prolongation of heart allograft survival is
mediated via sympathetic input to the spleen. As the present
conditioning paradigm produces a reduction in IL-2 and IFN-
secretion by proliferating splenocytes, we examined whether
conditioning was also able to mimic the effect of CsA on intracellular
IFN-
production.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
. Male DA rats were
placed on a water deprivation regimen for 5 days, allowing them 15 min
of drinking at 0700 and again at 1700 each day (Fig.
1A).
The present study implemented a three-learning (CS-UCS pairing)-trial
paradigm. Each learning trial was separated by 72 h. On the fifth day
animals received the first of three CS-UCS pairings. Conditioned
animals received 0.2% saccharin solution (Sac) as the CS paired with
20 mg/kg ip CsA as the UCS on the training days (Fig.
1C). In the afternoon session they
were administered water paired with intraperitoneal saline injection.
Sham-conditioned rats were given water paired with CsA in the morning
of the training days and Sac in combination with saline in the
afternoon. Three days after the final pairing, the CS alone was
presented during each drinking session. This was repeated for the
subsequent 2 days. Two extra control groups were implemented (Fig.
1C). CsA-treated animals were
treated similarly to sham-conditioned rats; however, these animals
received an additional CsA injection (20 mg/kg) after each of the first
three CS re-presentations. This allowed a comparison of the conditioned
response with the actual drug effect. Additionally, an untreated group
was used that was not manipulated during the entire conditioning
procedure. One hour after the third CS re-presentation, animals were
killed, and blood was drawn for analysis of corticosterone and CsA
levels. Additionally, the spleen was removed for examination of
intracellular IFN-
in splenocytes.

View larger version (19K):
[in a new window]
Fig. 1.
A: experimental design examining
effect of conditioning on intracellular interferon (IFN)-
production
and concentration of corticosterone and cyclosporin A (CsA) in blood.
Animals were habituated to experimental conditions for 3 wk and then
placed on water deprivation (see MATERIALS AND
METHODS). On 5th day animals received first of 3 conditioned stimulus (CS)-unconditioned stimulus (UCS) pairings. Three
days after final pairing, CS alone was presented during drinking
session. Animals were killed 1 h after third CS re-presentation, and
spleen and blood were collected for assay.
B: experimental design examining
effect of combination conditioning and subtherapeutic CsA on heart
allograft survival. Animals were conditioned with basic paradigm;
however, a 2 mg/kg ip dose of CsA was injected after CS
re-presentation. Heart allograft transplantation (Tx) was completed 1 h
after second 2 mg/kg administration of CsA after third CS
re-presentation. Subtherapeutic CsA administration was completed on 5 subsequent alternate days. CS was re-presented every day until
rejection of the graft. C:
experimental groups. Conditioned rats received a pairing of saccharin
(Sac) and CsA on CS-UCS days, with saccharin alone presented on CS
re-presentation days. Sham-conditioned rats were treated similarly to
conditioned animals, with the modification that they received water
(Wat) instead of saccharin. CsA-treated rats were conditioned in an
identical manner to sham-conditioned animals. However, on each of first
3 CS re-presentation days (CS1-CS3) they were administered a further
therapeutic dose of 20 mg/kg ip CsA. Untreated rats remained completely
unhandled.
Conditioning paradigm with subtherapeutic CsA: heart allograft survival. The conditioning paradigm examining heart allograft survival was similar to the paradigm used for cytokine measurement (Fig. 1B). However, this paradigm differed in that instead of killing the animals 1 h after the third CS presentation, animals received a heterotopic heart allograft. The CS was subsequently re-presented every day until rejection of the graft. Additionally, on the first CS re-presentation day, conditioned, sham-conditioned, and CsA-treated groups were injected with a 2 mg/kg ip (subtherapeutic) dose of CsA. This procedure was repeated on six further CS re-presentation days, with each subtherapeutic CsA administration separated by 48 h. Thus these groups received a subtherapeutic regimen of seven 2-mg/kg CsA injections [subtherapeutic CsA given after CS3 (day 16), CS5 (day 18), CS7 (day 20), CS9 (day 22), CS11 (day 24), and CS13 (day 26)]. Untreated rats were neither conditioned nor administered subtherapeutic CsA. Similar to the basic conditioning paradigm, CsA-treated animals received an additional CsA injection (20 mg/kg) after each of the first three CS re-presentations.
Conditioning paradigm: role of sympathetic innervation in conditioned heart allograft survival. To examine the role of splenic innervation in the effects of combination subtherapeutic CsA plus conditioning, the subtherapeutic heart allograft conditioning regimen was again implemented (Fig. 1B). However, 2 wk before conditioning, the spleens of animals from all groups were denervated of sympathetic innervation. Additionally, a group of animals receiving the main experimental treatment (conditioned-subtherapeutic CsA) were sham denervated. Conditioning, heart allograft transplantation, subtherapeutic CsA administration, and monitoring of survival were conducted in an identical manner.
Heterotopic heart transplantation. Transplantation was conducted using standard techniques (18). Briefly, the vena cava and the pulmonary veins of the donor rat (LEW rat; RT1l) were ligated, and the pulmonary artery and aorta were transected 2-3 mm above their origins. The heart was perfused with Ringer solution and placed in a 4°C saline bath. The abdominal vessels were dissected free in the anesthetized recipient rat (DA; RT1a) from the left renal vein to the bifurcation. The abdominal aorta and inferior vena cava were cross-clamped independently. The graft was placed into the abdominal cavity, and transplantation (donor aorta-recipient abdominal aorta; donor pulmonary artery-recipient inferior vena cava) was completed with end-to-side anastomoses. All grafts demonstrated good contractile function within 60 s of clamp removal. Grafts were palpated once daily to assess survival by an experimenter blind to the animals' treatment. Rejection was defined as the absence of a palpable heart beat.
Splenic denervation. Splenic denervation was conducted 2 wk before conditioning with standard techniques (20). Briefly, a midline incision opened the abdominal cavity, and the splenic nerve vascular package was exposed. The splenic nerve bundle was isolated from the splenic vasculature, and the neural bundle was cut before their bifurcation. The incision was then sutured, and the animal was allowed to recover. Sham denervation was completed by, again, isolating the splenic nerve bundle; however, the nerve was not sliced. Confirming previous data (8), splenic denervation reduced catecholamine content in the spleen to <20% of sham-denervated animals.
Corticosterone and CsA determination. One hour after the third CS re-presentation, blood was also collected for analysis of plasma corticosterone and CsA concentrations. Corticosterone concentrations were measured by radioimmunoassay as previously described (7). As previously detailed, concentrations of CsA and its metabolites (23) were assayed as double probes with commercial kits (Emit-test, Behring Diagnostic).
Intracellular IFN-
determination in T cell
subsets. DA rats were conditioned according to the
basic protocol (Fig. 1A), and animals that did not receive subtherapeutic CsA were killed 1 h after
the third CS re-presentation. The spleen was removed and, confirming
previous data (8), showed comparable cell numbers and B and T cell
subset composition among all groups (data not shown). Intracellular
IFN-
in splenic T cells was detected as described (17), with the
following modifications. Briefly, 2 × 106 splenocytes were incubated in
1 ng phorbol 12-myristate 13-acetate/ml and 250 ng Ionomycin (Sigma,
Diesenhofen, Germany) for 2 h. Then 2 µl Brefeldin A
(Golgiplug; Pharmingen, San Diego, CA) were added, and another 2-h
incubation period followed. After being washed in ice-cold PBS, the
cells were fixed in 2% formaldehyde for 20 min at room temperature.
The cells were subsequently incubated for 5 min in PBS containing 0.5%
saponin, 1% BSA, and 0.1% NaN3. To detect intracellular IFN-
the cells were incubated for 15 min at
room temperature with a mouse anti-rat IFN-
antibody (DB1; kindly
provided by P. van der Meide, The Netherlands), which was dissolved in
PBS containing 0.5% saponin, 1% BSA, and 0.1%
NaN3. After washing the cells were
incubated with PBS containing saponin, 10% rat serum, and 0.1%
NaN3 for 10 min, and a
phycoerythrin-conjugated anti-mouse antibody was used as a
second step antibody (30 min; dissolved in PBS containing 0.5%
saponin, 5% rat serum, and 0.1% NaN3). Subsequently,
CD4+ T cells (including their
"naive" and "memory" subsets) were identified via
appropriately conjugated antibodies against CD4 (W3/25) and CD45RC
(Ox22) as previously described (28). Isotype-matched irrelevant
antibodies served as controls. With the use of a FACScan and PC-LYSYS
software (Becton Dickinson, Mountain View, CA), the percentage of
IFN-
-positive cells was recorded in viable T cell subsets (2 × 104).
Statistical analyses. Heart allograft survival was analyzed by Kaplan-Meier logrank analysis for survival curve comparison. Average differences in graft survival between groups were analyzed with the nonparametric Kruskall-Wallis rank sum test, because data from conditioned animals violated the assumption of a normal distribution required for parametric statistical analysis. One-way ANOVAs were used to examine statistical differences between the four groups in hormonal and immunologic data. Post hoc Fisher's least significant difference tests were implemented to examine specific differences between groups. Values are presented as means ± SE. Statistically significant differences are reported when P < 0.05.
| |
RESULTS |
|---|
|
|
|---|
Behavioral conditioning enhances subtherapeutic CsA treatment. To investigate the effect of combination therapy (conditioning-CsA), we combined behavioral conditioning with a subtherapeutic CsA regimen. This was completed by conditioning the rats with 20 mg/kg CsA as the UCS (Fig. 1B) and additionally administering seven injections of 2 mg/kg ip CsA (subtherapeutic dose), which were injected on alternate days and commenced 2 days before transplantation (Fig. 1B).
Conditioned animals in the present paradigm avoid consumption of the saccharin stimulus after the first CS-UCS pairing (conditioned taste aversion) (8, 27). Such a response indicates acquisition of the association between the two stimuli, and was observed in the present series of experiments, in which conditioned animals typically drank <10% of the level of saccharin consumed by control animals. During assessment of graft survival, conditioned taste aversion extinguished between the 16th and 20th CS re-presentation (data not shown).
The mean graft survival time of heart allografts revealed that the
subtherapeutic CsA regimen alone was not effective, inasmuch as no
difference was observed between completely untreated animals and rats
receiving a combination of subtherapeutic CsA treatment and sham
conditioning (Fig.
2A).
In contrast, animals that received subtherapeutic CsA and were
behaviorally conditioned displayed a significant increase in survival
time compared with rats that received subtherapeutic CsA and were only
sham conditioned (P < 0.0001).
Furthermore, even a short course of therapeutic CsA treatment (3 × 20 mg/kg) together with the subtherapeutic regimen (7 × 2 mg/kg CsA) produced an increase in the mean survival time that was
significantly lower than that achieved by the combination of
subtherapeutic CsA and behavioral conditioning
(P < 0.001; Fig.
2C). The most striking effect
observed by combining conditioning and subtherapeutic CsA was
that 20% of these animals displayed long-term surviving grafts (>100
days).
|
Behavioral conditioning enhances subtherapeutic CsA
treatment via sympathetic innervation of the spleen. We
have previously shown that the present conditioning paradigm produces a
significant reduction in splenocyte proliferation and cytokine (IL-2,
IFN-
) production that is mediated via nerve fibers innervating the
spleen (8). Thus we examined whether autonomic innervation of the spleen influences the prolongation of heart allograft survival produced
by the combination of subtherapeutic CsA and conditioning. A second
independent experiment confirmed that conditioning plus subtherapeutic
CsA prolonged heart allograft survival, revealed in sham-denervated
rats. Furthermore, this replication again demonstrated that the
combination therapy induced long-term graft survival in 20% of the
animals. Moreover, splenic denervation completely abrogated the
increased survival time induced by the combination of subtherapeutic
CsA and behavioral conditioning (Fig. 2,
B and C; P < 0.0001).
Behavioral conditioning does not induce corticosterone
secretion or alter CsA metabolism. Psychological stress
activates the hypothalamus-pituitary-adrenal axis, resulting in the
release of glucocorticoids, which may potentially produce the current immunosuppression (29). Thus we examined whether conditioning may
enhance allograft survival via inducing the production of adrenal
steroids. We investigated this in nontransplanted, nonsubtherapeutic CsA-administered animals that were conditioned with the basic paradigm
(Fig. 1A). One hour after the
third conditioned stimulus re-presentation, blood was collected to
investigate glucocorticoid levels. Because no differences were observed
between the different experimental groups (Fig.
3A), it
is unlikely that conditioning-induced changes in glucocorticoid levels
are responsible for the prolonged allograft survival. To
ensure that conditioning did not produce immunosuppression via altering
CsA metabolism (9), we examined CsA levels at the same time. Only in
CsA-treated animals (3 × 20 mg · kg
1 · day
1)
was a detectable level of CsA (Fig.
3B) and CsA metabolites (Fig.
3C) revealed, indicating that
conditioning did not effect graft prolongation via altering CsA
metabolism.
|
Behavioral conditioning increases, and CsA decreases,
intracellular IFN-
in splenocytes. The present
conditioning paradigm has been shown to significantly reduce
mitogen-induced splenocyte proliferation and IL-2 and IFN-
levels in
the supernatant (8), the degree of reduction comparable to that
achieved by therapeutic CsA treatment (3 × 20 mg/kg). Because it
is likely that CsA treatment and behavioral conditioning prolong heart
allograft survival via different mechanisms, we further characterized
the effect of conditioning by examining the number of splenocytes
positive for intracellular IFN-
. We investigated this in
nontransplanted, nonsubtherapeutic CsA-administered animals that were
conditioned with the basic paradigm (Fig.
1A). Despite similar reductions in
extracellular cytokine levels in CsA-treated and conditioned rats (8),
only CsA-treated rats showed the expected reduction in the number of IFN-
-positive CD4+ splenocytes
(Fig.
4A). In
contrast, in conditioned animals a significant increase of
IFN-
-positive CD4+ splenocytes
was observed (Fig. 4A). This effect
was more pronounced in "memory" than in "naive"
CD4+ T cells (Fig. 4,
B and
C).
|
| |
DISCUSSION |
|---|
|
|
|---|
Our results demonstrate that behavioral conditioning can supplement subtherapeutic doses of CsA to prolong heart allograft survival in the rat. This is achieved by the central nervous system via autonomic innervation of the spleen. In two independent experiments, subtherapeutic doses of CsA combined with behavioral conditioning exceeded the level of graft prolongation achieved by the present conditioning paradigm in isolation (8), and 20% of the animals retained a fully functional allograft 100 days posttransplantation. Therefore, the present data indicate that behavioral conditioning produces a clinically meaningful alteration of heart allograft survival when combined with subtherapeutic CsA treatment.
Because splenic denervation completely abrogates the conditioned
prolongation of heart allograft survival, the spleen is important for
both receiving signals from the central nervous system during CS
re-presentation and mediating the subsequent immunosuppression. Sympathetic nerves are in close contact with lymphocytes in the spleen
(10, 25), and they release catecholamines that influence splenic IL-6
production (25) via functional adrenoceptors (3, 11, 14). In addition,
it is known that splenic T cell proliferation and synthesis of both
IL-2 and IFN-
can be reduced by sympathetic nervous system input
(15, 21). Furthermore, in the current conditioning paradigm, splenocyte
proliferation and the secretion of IL-2 and IFN-
from these cells is
reduced, although the cell number of lymphocyte subpopulations in the
spleen is unaltered. Because the release of cytokines (e.g., IL-2) from
CD4+ T cells activates
CD8+ T cells, which are
responsible for mediating allograft rejection in this model (13), it is
likely that conditioning contributes to graft prolongation via
suppression of the functional capacity of T cells within the spleen.
The current data demonstrate that conditioning does not increase the effectiveness of subtherapeutic CsA via inducing corticosteroid release or altering CsA metabolism. Behavioral paradigms potentially increase corticosteroid secretion as a result of stress. Corticosteroids then potentiate the suppression of immune functions and may synergize with CsA to prolong graft survival (5, 26). However, it is unlikely that stress-induced steroids are responsible for the present effect of subtherapeutic CsA, inasmuch as no differences in plasma corticosterone were observed between groups. It was also possible that conditioning may have been effective by altering CsA metabolism. Certain drugs increase the effectiveness of CsA via increasing its concentration in the blood (9, 24). However, detectable levels of CsA or its metabolites were only observed in CsA-treated rats, who received therapeutic CsA on the three CS re-presentation days.
Taken together, this evidence indicates that splenic innervation is
responsible for producing the conditioned alterations in immune
function, whereas the cellular mechanism is still unknown. However, a
possible clue may be provided by the finding that although behavioral
conditioning reduces IL-2 and IFN-
in the supernatant of
proliferating splenocytes without altering lymphocyte subpopulation cell numbers in the spleen (8), this paradigm actually increases the
number of CD4+ T cells that are
positive for intracellular IFN-
. This contrasts with CsA treatment,
which leads to the expected lower number of IFN-
-positive
splenocytes. Thus these data indicate that behavioral conditioning
promotes a different cellular action than CsA treatment. That is,
conditioning acts to inhibit cellular cytokine release, whereas CsA
induces its effect via arresting cytokine production. This may explain
the synergistic effect of combination subtherapeutic CsA and behavioral
conditioning in prolonging heart allograft survival. Similarly,
subtherapeutic doses of other immunosuppressants potentiate
subtherapeutic CsA, producing significant prolongation of graft
survival that is not possible with either drug dose administered in
isolation (4, 6, 24).
Although the current data showed that conditioning prolongs heart allograft survival, it cannot rule out the possibility that this effect was produced by the CS-UCS acquisition trials and not by CS re-presentation. However, this is unlikely, inasmuch as both conditioned and sham-conditioned animals received the same stimuli, albeit in different combinations, on CS-UCS acquisition days. Nevertheless, future research should account for this possibility by incorporating a conditioned group that does not receive the CS on re-presentation trials (1, 16, 19).
In summary, the current data show that behavioral conditioning and a
subtherapeutic CsA regimen synergize to prolong heart allograft
survival. Conditioning prolongs graft survival via a neural mechanism,
inasmuch as removal of sympathetic innervation of the spleen abrogates
the conditioned effect. The synergistic combination of conditioning and
subtherapeutic CsA may result from the distinct alterations of cytokine
production. That is, although CsA blocks IL-2 and IFN-
production,
conditioning may supplement this immunosuppression by limiting
extracellular cytokine release.
Perspectives
The data presented here demonstrate that behavioral conditioning may have practical implications in a clinical setting. Although conditioning paradigms have been shown to produce reliable alterations in immune function and to influence the course of a disease model in laboratory animals, the effects are typically small. Thus it is likely that for this interesting phenomenon to have any practical relevance, it must be combined with drug therapy with the aim of reducing the dose of medication required and thus possibly limiting unwanted drug side effects (e.g., Ref. 1). Therefore, this study shows that a dose of CsA that is previously ineffective in prolonging graft survival transforms to an effectual drug regimen when coupled with behavioral conditioning. These data demonstrate that behavioral models can be used as a supplement to immunomodulatory drug regimens. This information contributes to the ultimate goal of complementing pharmacotherapy by controlled behavioral paradigms in a clinical setting.| |
ACKNOWLEDGEMENTS |
|---|
We thank Anja Reu
e for expert technical assistance.
| |
FOOTNOTES |
|---|
Cyclosporin A was kindly donated by Novartis (Nürnberg, Germany).
This work was supported by Grant I/70 485 from the Volkswagen Foundation (to M. Schedlowski and J. Westermann) and a Research Fellowship from the Alexander von Humboldt Foundation (to M. S. Exton).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: M. Exton, Institute of Medical Psychology, Univ. Clinic Essen, Hufelandstr. 55, D-45122 Essen, Germany (E-mail: michael.exton{at}uni-essen.de).
Received 2 November 1998; accepted in final form 16 February 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ader, R.,
and
N. Cohen.
Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus.
Science
215:
1534-1536,
1982
2.
Ader, R.,
and
N. Cohen.
Psychoneuroimmunology: conditioning and stress.
Annu. Rev. Psychol.
44:
53-85,
1993[Medline].
3.
Benschop, R. J.,
M. Rodriguez-Feuerhahn,
and
M. Schedlowski.
Catecholamine-induced leukocytosis: early observations, current research, and future directions.
Brain Behav. Immun.
10:
77-91,
1996[Medline].
4.
Bolling, S. F.,
H. Lin,
R.-Q. Wie,
P. Linsley,
and
L. A. Turka.
The effect of combination cyclosporine and CTLA-Ig therapy on cardiac allograft survival.
J. Surg. Res.
57:
60-64,
1994[Medline].
5.
Briggs, W. A.,
Z. H. Gao,
L. F. Gimenez,
P. J. Scheel,
M. J. Choi,
and
J. F. Burdick.
Lymphocyte responsiveness to glucocorticoids, cyclosporine, or both.
J. Clin. Pharmacol.
36:
707-714,
1996[Abstract].
6.
Cosenza, C. A.,
D. V. Cramer,
G. Eiras-Hreha,
E. Cajulis,
H. K. Wang,
and
L. Makowka.
The synergism of brequinar sodium and cyclosporine used in combination to prevent cardiac allograft rejection in the rat.
Transplantation
56:
667-672,
1993[Medline].
7.
Del Rey, A.,
I. Klusman,
and
H. O. Besedovsky.
Cytokines mediate protective stimulation of glucocorticoid output during autoimmunity: involvement of IL-1.
Am. J. Physiol.
275 (Regulatory Integrative Comp. Physiol. 44):
R1146-R1151,
1998
8.
Exton, M. S.,
S. von Hörsten,
M. Schult,
J. Vöge,
T. Strubel,
S. Donath,
C. Steinmüller,
H. Seeliger,
E. Nagel,
J. Westermann,
and
M. Schedlowski.
Behaviorally conditioned immunosuppression using cyclosporin A: central nervous system reduces IL-2 production via splenic innervation.
J. Neuroimmunol.
88:
182-191,
1998[Medline].
9.
Faulds, D.,
K. L. Goa,
and
P. Benfield.
Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.
Drugs
45:
953-1040,
1993[Medline].
10.
Felten, D. L.,
S. Y. Felten,
D. L. Bellinger,
S. L. Carlson,
K. D. Ackerman,
K. S. Madden,
J. A. Olschowka,
and
S. Livnat.
Noradrenergic sympathetic neural interactions with the immune system: structure and function.
Immunol. Rev.
100:
225-260,
1987[Medline].
11.
Fuchs, B. A.,
K. S. Campbell,
and
A. E. Munson.
Norepinephrine and serotonin content of the murine spleen: its relationship to lymphocyte
-adrenergic receptor density and the humoral immune response in vivo and in vitro.
Cell. Immunol.
117:
339-351,
1988[Medline].
12.
Grochowicz, P. M,
M. Schedlowski,
A. J. Husband,
M. G. King,
A. D. Hibberd,
and
K. M. Bowen.
Behavioral conditioning prolongs heart allograft survival in rats.
Brain Behav. Immun.
5:
349-356,
1991[Medline].
13.
Hall, B. M.
Cells mediating graft rejection.
Transplantation
51:
1141-1151,
1991[Medline].
14.
Jetschmann, J.-U.,
R. J. Benschop,
R. Jacobs,
R. Oberbeck,
R. E. Schmidt,
and
M. Schedlowski.
Expression and in-vivo modulation of
- and
-adrenoceptors on human natural killer (CD16+) cells.
J. Neuroimmunol.
74:
159-164,
1997[Medline].
15.
Kruszewska, B.,
S. Y. Felten,
and
J. A. Moynihan.
Alterations in cytokine and antibody production following chemical sympathectomy in two strains of mice.
J. Immunol.
155:
4613-4620,
1995[Abstract].
16.
Luecken, L. J.,
and
D. T. Lysle.
Evidence for the involvement of
-adrenergic receptors in conditioned immunomodulation.
J. Neuroimmunol.
38:
209-220,
1992[Medline].
17.
Murphy, E.,
K. Shibuya,
N. Hosken,
P. Openshaw,
V. Maino,
K. Davis,
K. Murphy,
K.,
and
A. O'Garra.
Reversibility of T helper 1 and 2 populations is lost after long-term stimulation.
J. Exp. Med.
183:
901-913,
1996
18.
Ono, K.,
and
E. S. Lindsey.
Improved technique of heart transplantation in rats.
J. Thorac. Cardiovasc. Surg.
57:
225-229,
1969[Medline].
19.
Perez, L.,
and
D. T. Lysle.
Conditioned immunomodulation: investigations of the role of endogenous activity at µ,
, and
opioid receptor subtypes.
J. Neuroimmunol.
79:
101-112,
1997[Medline].
20.
Rogausch, H.,
A. del Rey,
A. Kabiersch,
W. Reschke,
J. Örtel,
and
H. Besedovsky.
Endotoxin impedes vasoconstriction in the spleen: role of endogenous interleukin-1 and sympathetic innervation.
Am. J. Physiol.
272 (Regulatory Integrative Comp. Physiol. 41):
R2048-R2054,
1997
21.
Sanders, V. M.,
R. A. Baker,
D. Ramer-Quinn,
D. J. Kasprowicz,
B. A. Fuchs,
and
N. E. Street.
Differential expression of the
2-adrenergic receptor by Th1 and Th2 clones.
J. Immunol.
158:
4200-4210,
1997[Abstract].
22.
Schedlowski, M.,
W. Hosch,
R. Oberbeck,
R. J. Benschop,
R. Jacobs,
H.-R. Raab,
and
R. E. Schmidt.
Catecholamines modulate human NK cell circulation and function via spleen-independent
2-adrenergic mechanisms.
J. Immunol.
156:
93-99,
1996[Abstract].
23.
Schumann, G.,
D. Petersen,
P. F. Hoyer,
and
K. Wonigeit.
Monitoring cyclosporin A (Ciclosporin, INN) concentrations in whole blood: evaluation of the EMIT assay in comparison with HPLC and RIA.
Eur. J. Clin. Chem. Clin. Biochem.
31:
381-388,
1993[Medline].
24.
Stepkowski, S. M.,
L. Tian,
K. L. Napoli,
R. Ghobrial,
M. E. Wang,
T. C. Chou,
and
B. D. Kahan.
Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection.
Clin. Exp. Immunol.
108:
63-68,
1997[Medline].
25.
Straub, R. H.,
J. Westermann,
J. Schölmerich,
and
W. Falk.
Communication between CNS and immune system in lymphoid organs: synaptic dialogue with macrophages and lymphocytes.
Immunol. Today
19:
409-413,
1998[Medline].
26.
Vathsala, A.,
T. C. Chou,
and
B. D. Kahan.
Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation.
Transplantation
49:
463-472,
1990[Medline].
27.
von Hörsten, S.,
M. S. Exton,
M. Schult,
E. Nagel,
M. Stalp,
G. Schweitzer,
J. Vöge,
A. del Rey,
M. Schedlowski,
and
J. Westermann.
Behaviorally conditioned effects of cyclosporin A on the immune system of rats: specific alterations of blood leukocyte numbers and decrease of granulocyte function.
J. Neuroimmunol.
85:
193-201,
1998[Medline].
28.
Westermann, J.,
S. Persin,
J. Matyas,
P. van der Meide,
and
R. Pabst.
Migration of so-called naive and memory T lymphocytes from blood to lymph in the rat.
J. Immunol.
152:
1744-1750,
1994[Abstract].
29.
Wilckens, T.,
and
R. De Rijk.
Glucocorticoids and immune function: unknown dimensions and new frontiers.
Immunol. Today
18:
418-424,
1997[Medline].
This article has been cited by other articles:
![]() |
G. Pacheco-Lopez, C. Riether, R. Doenlen, H. Engler, M.-B. Niemi, A. Engler, A. Kavelaars, C. J. Heijnen, and M. Schedlowski Calcineurin inhibition in splenocytes induced by pavlovian conditioning FASEB J, April 1, 2009; 23(4): 1161 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. U. GOEBEL, A. E. TREBST, J. STEINER, Y. F. XIE, M. S. EXTON, S. FREDE, A. E. CANBAY, M. C. MICHEL, U. HEEMANN, and M. SCHEDLOWSKI Behavioral conditioning of immunosuppression is possible in humans FASEB J, December 1, 2002; 16(14): 1869 - 1873. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Exton, A. Elfers, W.-Y. Jeong, D. F. Bull, J. Westermann, and M. Schedlowski Conditioned suppression of contact sensitivity is independent of sympathetic splenic innervation Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2000; 279(4): R1310 - R1315. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |